← 返回专利悬崖列表
CAS 105-53-3
diethyl malonateCarbethoxyacetic ester1,3-Diethyl propanedioate
登记编号：MRIO-011、(III)638294-4-a、(VI)169995-7-a、(IX)169995-10-a、(IIIb)169995-24-a、Lercanidipine Hydrochloride-017、Tilidine Hydrochloride-002、ALOG-012、ETRA-007、POSA-010、D-RUXO-002、PREG-012 等 14 个
应用背景（按来源药适应症）
糖尿病神经病变苯磺酸美洛加巴林疱疹后神经痛苯磺酸美洛加巴林周围神经系统疾病苯磺酸美洛加巴林收缩性心力衰竭非奈利酮舒张期心力衰竭非奈利酮心脏衰竭非奈利酮慢性肾功能不全非奈利酮糖尿病肾病非奈利酮二型糖尿病非奈利酮避孕屈螺酮口腔炎，口疮屈螺酮经前焦虑性障碍屈螺酮经前期综合征屈螺酮痛经屈螺酮抑郁屈螺酮原发性高血压缬沙坦/盐酸乐卡地平疼痛盐酸替立定二型糖尿病苯甲酸阿格列汀糖尿病苯甲酸阿格列汀急性冠脉综合征苯甲酸阿格列汀HIV感染依曲韦林弗里德赖希共济失调依曲韦林炎性疾病依曲韦林胰岛素抵抗依曲韦林念珠菌病泊沙康唑曲霉菌属感染泊沙康唑真菌感染泊沙康唑口腔念珠菌病泊沙康唑球孢菌病泊沙康唑组织胞浆菌病泊沙康唑高血压盐酸乐卡地平斑秃氘代芦可替尼肾功能不全氘代芦可替尼肝功能衰退氘代芦可替尼纤维肌痛普瑞巴林癫痫发作普瑞巴林疱疹后神经痛普瑞巴林神经痛普瑞巴林癫痫部分性发作普瑞巴林糖尿病神经病变普瑞巴林肺结核TBA-7371结核分枝杆菌感染TBA-7371头颈部鳞状细胞癌Buparlisib实体瘤Buparlisib鼻咽肿瘤Buparlisib喉肿瘤Buparlisib口咽肿瘤Buparlisib鳞状细胞癌Buparlisib
来源药（使用该中间体的合成路线）
| 品种 | 梯队 | 到期年 |
|---|---|---|
| 苯磺酸美洛加巴林Mirogabalin besilate | Tier C · 观察 / 贸易 | 2030 |
| 非奈利酮Finerenone | Tier C · 观察 / 贸易 | 2030 |
| 屈螺酮Drospirenone | Tier C · 观察 / 贸易 | - |
| 缬沙坦/盐酸乐卡地平Valsartan/Lercanidipine Hydrochloride | Tier C · 观察 / 贸易 | - |
| 盐酸替立定Tilidine Hydrochloride | Tier C · 观察 / 贸易 | - |
| 苯甲酸阿格列汀Alogliptin Benzoate | Tier C · 观察 / 贸易 | - |
| 依曲韦林Etravirine | Tier C · 观察 / 贸易 | - |
| 泊沙康唑Posaconazole | Tier C · 观察 / 贸易 | - |
| 盐酸乐卡地平Lercanidipine Hydrochloride | Tier C · 观察 / 贸易 | - |
| 氘代芦可替尼Deuterated ruxolitinib | Tier C · 观察 / 贸易 | - |
| 普瑞巴林Pregabalin | Tier B · 提前布局 | - |
| TBA-7371 | Tier C · 观察 / 贸易 | - |
| Buparlisib | Tier C · 观察 / 贸易 | - |
合成路线中的位置（上下游链）
按路线登记顺序排列，左→右为合成方向；高亮为当前 CAS，其余可点击跳转对应档案。
(1R,5S)-3-ethylbicyclo[3.2.0]hept-3-en-6-one→diethyl malonate→diethyl 2-((1R,5S)-3-ethylbicyclo[3.2.0]hept-3-en-6-ylidene)malonate→diethyl 2-((1R,5S,6R)-6-cyano-3-ethylbicyclo[3.2.0]hept-3-en-6-yl)malonate→2-((1R,5S,6S)-6-cyano-3-ethylbicyclo[3.2.0]hept-3-en-6-yl)acetic acid→phenylmethanamine 2-((1R,5S,6S)-6-cyano-3-ethylbicyclo[3.2.0]hept-3-en-6-yl)acetate
4-Amino-5-methylpyridin-2(1H)-one→2-Methoxy-4-cyanobenzaldehyde→Carbethoxyacetic ester→Ethyl 4-(4-cyano-2-methoxyphenyl)-2,8-dimethyl-5-oxo-1,4,5,6-tetrahydro-1,6-naphthyridine-3-carboxylate→(Diethoxymethoxy)ethane→Ethyl 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxylate→4-(5-Ethoxy-3-formyl-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-4-yl)-3-methoxybenzonitrile→Ethyl (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxylate→(5aR,10bS)-2-(2,6-Dimethoxyphenyl)-6,10b-dihydro-4H,5aH-indeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazin-2-ium tetrafluoridoborate(1-)
(2R,12S,15S)-12-hydroxy-2,15-dimethyltetracyclo[8.7.0.0(2,7).0(11,15)]heptadec-6-ene-5,14-dione→(2R,12S,15S)-2,15-dimethyl-5,14-dioxotetracyclo[8.7.0.0(2,7).0(11,15)]heptadec-6-en-12-yl acetate→(2R,12S,15S)-5-methoxy-2,15-dimethyl-14-oxotetracyclo[8.7.0.0(2,7).0(11,15)]heptadeca-5,7-dien-12-yl acetate→(3S,5S,7S,11R)-14-methoxy-7,11-dimethylpentacyclo[8.8.0.0(2,7).0(3,5).0(11,16)]octadeca-14,16-dien-6-one→(3'S,5'S,7'S,11'R)-14'-methoxy-7',11'-dimethylspiro[oxirane-2,6'-pentacyclo[8.8.0.0(2,7).0(3,5).0(11,16)]octadecane]-14',16'-diene→Carbethoxyacetic ester→ethyl (3'S,5'S,7'S,11'R)-14'-methoxy-7',11'-dimethyl-5-oxospiro[oxolane-2,6'-pentacyclo[8.8.0.0(2,7).0(3,5).0(11,16)]octadecane]-14',16'-diene-4-carboxylate→ethyl (2S,3'S,5'S,7'S,11'R)-7',11'-dimethyl-5,14'-dioxospiro[oxolane-2,6'-pentacyclo[8.8.0.0(2,7).0(3,5).0(11,16)]octadecane]-15',17'-diene-4-carboxylate→ethyl (2R,4R,10R,14S,15S,16S,18S)-10,14-dimethyl-5',7-dioxospiro[hexacyclo[9.8.0.0(2,4).0(5,10).0(14,19).0(16,18)]nonadecane-15,2'-oxolan]-5-ene-4'-carboxylate
(3aS,3bR,9aR,9bS,11aS)-9a,11a-Dimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthrene-1,7-dione→(8R,9S,10R,13S,14S)-3-Ethoxy-10,13-dimethyl-1,2,7,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-one→3-Ethoxy-16-(phenylsulfinyl)androsta-3,5-dien-17-one→16-(Phenylsulfinyl)androst-4-ene-3,17-dione→Androsta-4,15-diene-3,17-dione→(4aR,4bS,6aS,7aS,8aS,8bR,8cR)-4a,6a-Dimethyl-4,4a,4b,6,6a,7a,8,8a,8b,8c,9,10-dodecahydrocyclopropa[4,5]cyclopenta[1,2-a]phenanthrene-2,7(3H,5H)-dione→(4aR,4bS,6aS,7aS,8aS,8bS,8cR)-4a,6a-Dimethyl-4,4a,4b,6,6a,7a,8,8a,8b,8c-decahydrocyclopropa[4,5]cyclopenta[1,2-a]phenanthrene-2,7(3H,5H)-dione→6beta,7beta,15beta,16beta-Dimethylene-17beta-spirooxiranoandrost-4-en-3-one→Carbethoxyacetic ester→(1R,2R,4R,10R,11S,14S,15S,16S,18S,19S)-10,14-Dimethyl-5',7-dioxospiro[hexacyclo[9.8.0.0(2,4).0(5,10).0(14,19).0(16,18)]nonadecane-15,2'-oxolan]-5-ene-4'-carboxylic acid
(1aR,1bR,3S,5aR,5bS,7aS,8aS,9aS,9bS,9cR,9dR)-1b,3-Dihydroxy-5a,7a-dimethylperhydrocyclopropa[4,5]cyclopenta[1,2-a]cyclopropa[l]phenanthren-8-one→(1aR,1bR,3S,5aR,5bS,7aS,8S,8aS,9aS,9bS,9cR,9dR)-5a,7a-Dimethylhexadecahydrospiro[cyclopropa[4,5]cyclopenta[1,2-a]cyclopropa[l]phenanthrene-8,2'-oxirane]-1b,3(2H)-diol→3-(Ethoxycarbonyl)-2-oxopropan-1-ide→Carbethoxyacetic ester→Sodium 3-ethoxy-3-oxopropanoate→(1aR,1bR,3S,5aR,5bS,7aS,8R,8aS,9aS,9bS,9cR,9dR)-1b,3-Dihydroxy-5a,7a-dimethyl-5'-oxoicosahydro-3'H-spiro[cyclopropa[4,5]cyclopenta[1,2-a]cyclopropa[l]phenanthrene-8,2'-furan]-3'-carboxylic acid→Ethyl (1aR,1bR,3S,5aR,5bS,7aS,8R,8aS,9aS,9bS,9cR,9dR)-1b,3-dihydroxy-5a,7a-dimethyl-5'-oxoicosahydro-3'H-spiro[cyclopropa[4,5]cyclopenta[1,2-a]cyclopropa[l]phenanthrene-8,2'-furan]-3'-carboxylate→(1aR,1bR,5aR,5bS,7aS,8R,8aS,9aS,9bS,9cR,9dR)-1b-Hydroxy-5a,7a-dimethyl-3,5'-dioxoicosahydro-3'H-spiro[cyclopropa[4,5]cyclopenta[1,2-a]cyclopropa[l]phenanthrene-8,2'-furan]-3'-carboxylic acid→Ethyl (1aR,1bR,5aR,5bS,7aS,8R,8aS,9aS,9bS,9cR,9dR)-1b-hydroxy-5a,7a-dimethyl-3,5'-dioxoicosahydro-3'H-spiro[cyclopropa[4,5]cyclopenta[1,2-a]cyclopropa[l]phenanthrene-8,2'-furan]-3'-carboxylate→Sodium (1aR,1bR,3S,5aR,5bS,7aS,8R,8aS,9aS,9bS,9cR,9dR)-1b,3-dihydroxy-5a,7a-dimethyl-5'-oxoicosahydro-3'H-spiro[cyclopropa[4,5]cyclopenta[1,2-a]cyclopropa[l]phenanthrene-8,2'-furan]-3'-carboxylate→Sodium (1aR,1bR,5aR,5bS,7aS,8R,8aS,9aS,9bS,9cR,9dR)-1b-hydroxy-5a,7a-dimethyl-3,5'-dioxoicosahydro-3'H-spiro[cyclopropa[4,5]cyclopenta[1,2-a]cyclopropa[l]phenanthrene-8,2'-furan]-3'-carboxylate
本站可供应的对应中间体
同 CAS 多家在售供应横向对比；价格区间为供应方挂牌口径，实价以询价确认为准。
| 供应商 | 产品 | 价格区间 | 最小起订 | 货期 | 资质 | 操作 |
|---|---|---|---|---|---|---|
| Unibest Nantong cGMP Site | 4-Bromo-2-methoxybenzaldehyde Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — | |
| Unibest Taizhou GMP-like Site | 4-formyl-3-methoxybenzonitrile Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — | |
| Qualified Partner — East China API Works | 4-AMino-5-Methylpyridin-2-ol Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — | |
| Unibest Nantong cGMP Site | 2-chloro-5-methylpyridin-4-amine Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — | |
| Unibest Taizhou GMP-like Site | 2-Cyanoethyl 3-oxobutanoate Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — | |
| Qualified Partner — East China API Works | 2-cyanoethyl 4-(4-cyano-2-methoxyphenyl)-2,8-dimethyl-5-oxo-1,4,5,6-tetrahydro-1,6-naphthyridine-3-carboxylate Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — | |
| Qualified Partner — East China API Works | (1R,5S)-3-ethyl-Bicyclo[3.2.0]hept-3-en-6-one Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — | |
| Unibest Nantong cGMP Site | 3-ethylbicyclo[3.2.0]hept-3-en-6-one Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
本页为中间体 CAS 注册档案：同 CAS 的多条路线登记已合并；后续供应商报价与买方需求以该 CAS 为主键撮合。